Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof

Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof

US Patent 11639386 · Granted May 2, 2023

Estimated economic value: $10,664,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

CD137 binding molecules and uses thereof2025
CD137 binding molecules and uses thereof2025
ILT-binding agents and methods of use thereof2025
Bispecific molecules comprising an HIV-1 envelope targeting arm2024
Bispecific molecules comprising an HIV-1 envelope targeting arm2024
Bispecific molecules comprising an HIV-1 envelope targeting arm2024
Bispecific molecules comprising an HIV-1 envelope targeting arm2024
CD3-binding molecules capable of binding to human and non-human CD32024
HER2/neu-specific antibodies and methods of using same2024
HER2/neu-specific antibodies and methods of using same2024
Bispecific binding molecules that are capable of binding CD137 and tumor antigen2024
Bispecific binding molecules that are capable of binding CD137 and tumor antigen2024